June 5, 2017 09:00 AM EDT

With one BLA at the FDA, Kite hustles along impressive new leukemia data and sounds a note of caution on safety

John Carroll

Editor & Founder

CHICAGO — With its lead program for non-Hodgkin lymphoma in front of FDA reviewers, Kite Pharma $KITE today updated their Phase I CAR-T study on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With one BLA at the FDA, Kite hustles along impressive new leukemia data and sounds a note of caution on safety

John Carroll

Editor & Founder

Sign up to read this article for free.

Moderna reports slow start to RSV sales as Bancel steps back from commercial role

Sarepta discontinues work on next-gen exon-skipping drug for Duchenne

Biotech industry worries over potential for RFK Jr. ally as FDA pick

GSK CEO Emma Walmsley on the new Trump administration, trust, AI and China

Joe Jimenez's latest Aditum company lines up T cell engager from China

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

With one BLA at the FDA, Kite hus­tles along im­pres­sive new leukemia da­ta and sounds a note of cau­tion on safe­ty

John Carroll

Editor & Founder

Sign up to read this article for free.

Mod­er­na re­ports slow start to RSV sales as Ban­cel steps back from com­mer­cial role

Sarep­ta dis­con­tin­ues work on next-gen ex­on-skip­ping drug for Duchenne

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

GSK CEO Em­ma Walm­s­ley on the new Trump ad­min­is­tra­tion, trust, AI and Chi­na

Joe Jimenez's lat­est Adi­tum com­pa­ny lines up T cell en­gager from Chi­na

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

With one BLA at the FDA, Kite hustles along impressive new leukemia data and sounds a note of caution on safety

Moderna reports slow start to RSV sales as Bancel steps back from commercial role

Sarepta discontinues work on next-gen exon-skipping drug for Duchenne

Biotech industry worries over potential for RFK Jr. ally as FDA pick

GSK CEO Emma Walmsley on the new Trump administration, trust, AI and China

Joe Jimenez's latest Aditum company lines up T cell engager from China

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks